Onychin inhibits proliferation of vascular smooth muscle cells by regulating cell cycle

Acta Pharmacologica Sinica

Volumn 26, Issue 2, 2005, Pages 205-210

  Yang, Ming ^a   Huang, Hong Lin ^a   Zhu, Bing Yang ^a   Tuo, Qin Hui ^a   Liao, Duan Fang ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Cell cycle; Cyclin D 1; Cyclin E; Mitogen activated protein kinase; Onychin; Retinoblastoma; Tyrosine kinase; Vascular smooth muscle

Indexed keywords

ANTIBODY; CYCLIN D1; CYCLIN E; GENISTEIN; HERBACEOUS AGENT; MITOGEN ACTIVATED PROTEIN KINASE 3; ONYCHIN; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; IMMUNOPRECIPITATION; MALE; METABOLIC RATE; MITOSIS INHIBITION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 13444254354     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00526.x     Document Type: Article

References (27)

1. Lin MW, Roubin GS, King SB III. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-87.
2. Ohlstein EH, Douglas SA, Sung CP, Yue T, Louden C, Arleth A, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993; 93: 6189-93.
3. Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, Fumagalli R, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996; 87: 458-68.
4. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxy-nucleotides. J Clin Invest 1994; 93: 820-8.
5. Pan W, Ikeda K, Takebe M, Yamori Y. Genistein, daidzein and glycitein inhibit growth and DNA synthesis of aortic smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Nutri 2001; 131: 1154-8.
6. Polkowski K, Mazurek AP. Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol Pharm 2000; 57: 135-55.
7. Wang HK. The therapeutic potential of flavonoids. Expert Opin Investig Drugs 2000; 9: 2103-19.
8. Xu YL, Isao K, Ma YB. Acytotoxic flavanone glycoside from onychiun japonicum: structure of onychin. Phytochemistry 1993; 33: 510-1.
9. Tuo QH, Huang HL, Xie ZZ. Protection of onychin on injury of endothelium-dependent relaxion induced by lysophosphatidylcholine. Chin J Arterioscler 2001; 9: 27-30.
10. Tuo QH, Liao DF, Zhu BY, Yan FX. Protective effects of onychin on vascular endothelial cell injured by oxidative stress. Chin J Clin Pharmacol Ther 2003; 8: 381-4
11. Guo Y, Zhu BY, Yan FX, Liao DF. Protective action of onychin against growth inhibition of endothelial cell injured by oxidation and its mechanism. Chin Pharmacol Bull 2003; 19: 401-3.
12. Guo Y, Zhu BY, Yan FX, Huang HL, Liao DF. Protective effects of onychin on the human umbilical vein endothelial cell injured by menadione. Chin J Pathophysiol 2003; 19: 10-3.
13. Tuo QH, Wang C, Yan FX, Liao DF. MAPK pathway mediates the protective effects of onychin on oxidative stress-induced apoptosis in ECV304 endothelial cells. Life Sci 2004; 76: 487-97.
14. Tu YS, Huang HL, Zhu BY, Liao DF. Enzymatic dispersion method of primary culture of rat aortic vascular smooth muscle cells. Chin J Arterioscler 2001; 9: 438-40.
15. Liao DF, Monia B, Dean N, Berk BC. Protein kinase C-ζ mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem 1997; 272: 6146-50.
16. Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R, et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000; 275: 189-96.
17. Goodrich DW, Lee WH. Molecular characterization of the retinoblastoma susceptibility gene. Biochim Biophys Acta 1993; 1155: 43-61.
18. 2 promoter repression and pRb-mediated growth suppression. Mol Cell Biol 1993; 13: 3384-91.
19. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Annu Rev Physiol 1998; 60: 601-17.
20. Chang MW, Barr E, Seltzer J, Nabel GJ, Nabel GJ, Parmacek MS, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-22.
21. 2F family: protein structure and gene regulation. Curr Top Microbiol Immunol 1996; 208: 1-30.
22. 1 phase progression: cycling on cue. Cell 1994; 79: 551-5.
23. Lu B, Dai YM. Abnormal cycle regulation of cells in the HCC. World J Gastroenterol 2001; 9: 205-8.
24. Ishizuka S, Yano T, Hagiwara K, Sone M, Nihei H, Ozasa H, et al. Extracellular signal-regulated kinase mediates renal regeneration in rats with myoglobinuric acute renal injury. Biochem Biophys Res Commun 1999; 254: 88-92.
25. Kronemann N, Nockher WA, Busse R, Schini-Kerth VB. Growth-inhibitory effect of cyclic GMP- and cyclic AMP-dependent vasodilators on rat vascular smooth muscle cells: effect on cell cycle and cyclin expression. Br J Pharmacol 1999; 126: 349-57.
26. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995; 9: 726-35.
27. Huang CY, Ferrell JE Jr. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1996; 93: 10078-83.